Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added a dedicated Locations section listing California, Massachusetts, and New York; removed separate state location headers and updated the revision from v3.3.2 to v3.3.3.
    Difference
    0.4%
    Check dated 2025-12-23T21:15:22.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    Publications section updated to indicate items are automatically filled from PubMed. Revision tag updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-25T10:47:03.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Removal of the government funding lapse notice and related operating-status guidance from the page; study data and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T06:55:41.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Non-substantive differences seem to be formatting and layout changes across the page; there are no edits to the study purpose, criteria, interventions, or outcomes. Core details such as the title, NCT number, enrollment, locations, and status remain as before. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T20:54:37.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Core content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.
    Difference
    2%
    Check dated 2025-10-06T05:08:06.000Z thumbnail image
  9. Check
    100 days ago
    Change Detected
    Summary
    The page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.
    Difference
    0.1%
    Check dated 2025-09-29T02:56:55.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.